Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Oct;89(4):750-4.
doi: 10.4269/ajtmh.13-0096. Epub 2013 Aug 26.

In vitro susceptibility of Leishmania donovani to miltefosine in Indian visceral leishmaniasis

Vijay Kumar Prajapati  1 , Smriti Sharma, Madhukar Rai, Bart Ostyn, Poonam Salotra, Manu Vanaerschot, Jean-Claude Dujardin, Shyam Sundar
Affiliations

In vitro susceptibility of Leishmania donovani to miltefosine in Indian visceral leishmaniasis

Vijay Kumar Prajapati et al. Am J Trop Med Hyg. 2013 Oct.

Abstract

Promastigote miltefosine (MIL) susceptibility was performed on Leishmania donovani isolates from Indian patients with visceral leishmaniasis treated with MIL. Isolates that were obtained before the onset of MIL treatment, after completion of treatment (29th day), or at the time of treatment failure, were screened using in vitro promastigote assay. The MIL susceptibility of the pre-treatment isolates (N = 24, mean IC50 ± SEM = 3.74 ± 0.38 μM) was significantly higher than that of the post-treatment group (N = 26, mean IC50 ± SEM = 6.15 ± 0.52 μM; P = 0.0006) but was similar in the cured patients (N = 22, mean IC50 ± SEM = 5.58 ± 0.56 μM) and those who failed treatment (N = 28, mean IC50 ± SEM = 4.53 ± 0.47 μM). The pre/post-treatment results thus showed a 2-fold difference, whereas isolated from cured versus failed patients showed a similar susceptibility, suggesting that this higher tolerance is not responsible for MIL-treatment failure. Our work highlights the need for careful monitoring of MIL susceptibility for implementation in national VL elimination programs.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Miltefosine susceptibility assay was performed between the group of Leishmania donovani isolates patients destined to cure and patients destined to fail from pre- and post-treatment group of subjects.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Alvar J, Velez ID, Herrero M, Desjeux P, Cano J, Janin J, den Boer M. WHO Leishmaniasis Control Team Leishmaniasis worldwide and global estimates of its incidence. PLoS ONE. 2012;7:e35671. - PMC - PubMed
    1. Guerin PJ, Olliaro P, Sundar S, Boelaert M, Croft SL, Desjeux P, Wasunna MK, Bryceson AD. Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect Dis. 2002;2:494–501. - PubMed
    1. Joshi A, Narain JP, Prasittisuk C, Bhatia R, Hashim G, Jorge A, Banjara M, Kroeger A. Can visceral leishmaniasis be eliminated from Asia? J Vector Borne Dis. 2008;45:105–111. - PubMed
    1. WHO . Expert Committee on Regional Strategic Framework for Elimination of Kala-azar from the South-East Asia Region (2005–2015) New Delhi: WHO regional Office for South-East Asia; 2005.
    1. Prajapati VK, Awasthi K, Gautam S, Yadav TP, Rai M, Srivastava ON, Sundar S. Targeted killing of Leishmania donovani in vivo and in vitro with amphotericin B attached to functionalized carbon nanotubes. J Antimicrob Chemother. 2011;66:874–879. - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources